Novonesis, operating through Novozymes A/S, effectively priced and finalized a total principal of EUR 1.7 billion senior unsecured notes, referred to as the "Notes," on March 12, 2026. This transaction took place under the recently created EUR 4 billion Euro Medium Term Note (EMTN) Programme which was dated March 10, 2026.